BioSpace News Archive

Seamless payroll integration as a key Sandata differentiator

- Chicago Area Studios Named a Top Contributor for Augie’s Quest During Second Annual Brand-Wide Fundraising Campaign -

The U.S. Food and Drug Administration granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD).

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer.

BLINCYTO is the First-and-Only FDA-Approved Therapy for Minimal Residual Disease Detection of Remaining Cancer Cells After Complete Remission is the Strongest Prognostic Factor for Relapse in Patients With Acute Lymphoblastic Leukemia Accelerated Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia

Results of Porous PEEK™ impaction durability study now available in The Spine Journal

MIVI Neuroscience, Inc. announced it has received CE Mark approval for the R4Q Revascularization Catheter for the removal of fresh, soft emboli and thrombi in the peripheral and neurovascular systems.

-Pulmatrix, Inc. announced the pricing of an underwritten public offering of an aggregate of 23,500,000 units.

Dr. Reddy’s Laboratories Ltd. announced a change in the makeup of its senior leadership team.

Karthik adds a new dimension to the company that will allow for the execution of key priorities enabling EmpiRx Health to achieve its vision.